Copyright
©The Author(s) 2015.
World J Gastroenterol. Oct 21, 2015; 21(39): 11168-11178
Published online Oct 21, 2015. doi: 10.3748/wjg.v21.i39.11168
Published online Oct 21, 2015. doi: 10.3748/wjg.v21.i39.11168
Figure 1 Treatment schedule for patients with pancreatic ductal adenocarcinoma.
The patients were treated with gemcitabine alone, followed by dendritic cells pulsed with a Wilms’ tumor 1 (WT1)-specific peptide mixture restricted by multiple major histocompatibility complex (MHC) class I and II molecules (DC/WT1-I/II) in combination with gemcitabine or S-1, an oral 5-fluorouracil (5-FU). GEM: Gemcitabine.
- Citation: Tsukinaga S, Kajihara M, Takakura K, Ito Z, Kanai T, Saito K, Takami S, Kobayashi H, Matsumoto Y, Odahara S, Uchiyama K, Arakawa H, Okamoto M, Sugiyama H, Sumiyama K, Ohkusa T, Koido S. Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy. World J Gastroenterol 2015; 21(39): 11168-11178
- URL: https://www.wjgnet.com/1007-9327/full/v21/i39/11168.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i39.11168